Retatrutide vs Tirzepatide: A Head-to-Head Data Comparison

Retatrutide and tirzepatide are the two most aggressive incretin therapies in the Eli Lilly pipeline. Tirzepatide is the current commercial leader: FDA-approved as Mounjaro (type 2 diabetes, May 2022) and Zepbound (obesity, November 2023), with the strongest efficacy data of any approved weight loss drug. SURMOUNT-1 (Jastreboff et al., NEJM, 2022) put the 15mg dose at 22.5% mean body weight reduction over 72 weeks. Retatrutide is investigational. Its first Phase III readout, TRIUMPH-4 (NCT05931367), reported in December 2025 with the 12mg dose at 28.7% over 68 weeks.

Six percentage points separate the two headline figures. That matters less in isolation than it does relative to the tirzepatide vs semaglutide gap, which was roughly 7 to 8 percentage points in the SURMOUNT-5 head-to-head trial (20.2% vs 13.7%). In other words: the move from dual to triple agonism produces a smaller incremental gain than the move from single to dual agonism did. The law of diminishing returns may apply at the receptor level, and that has implications for how clinicians, patients, and investors should think about retatrutide's eventual market position.

This article walks through the mechanisms, the trial evidence, the dosing and tolerability picture, and the practical context. All figures below come from published trial data or Eli Lilly's December 2025 press release, with sources cited throughout.

What the two compounds are

Tirzepatide is a dual agonist at GLP-1 and GIP receptors. GLP-1 (glucagon-like peptide-1) activation slows gastric emptying, stimulates glucose-dependent insulin release, reduces glucagon secretion, and acts centrally on appetite. GIP (glucose-dependent insulinotropic polypeptide) activation enhances insulin secretion and appears to have synergistic effects with GLP-1 in adipose tissue, particularly on lipid handling. Tirzepatide was the first approved dual incretin receptor agonist and is marketed by Eli Lilly as Mounjaro (type 2 diabetes) and Zepbound (obesity).

Retatrutide (Eli Lilly's LY3437943) adds a third receptor: glucagon. Glucagon receptor activation in the liver and adipose tissue is thought to increase basal energy expenditure and promote fat oxidation. Tirzepatide reduces calorie intake through GLP-1 plus modulates adipose metabolism through GIP. Retatrutide does both of those things and then adds a metabolic rate lever on top. The mechanistic argument for the extra weight loss is that appetite suppression eventually plateaus, but raising basal metabolic rate does not plateau in the same way, at least over trial timelines.

Both compounds are lipidated peptides engineered for once-weekly subcutaneous dosing. Tirzepatide's half-life is approximately 5 days. Retatrutide's is roughly 6 days. Both use prefilled pens in their trial and commercial presentations. Neither has an oral formulation for weight loss, though Lilly is separately advancing orforglipron as an oral GLP-1 agonist.

What the research says

The fairest comparison is each compound's pivotal Phase III obesity trial, running under broadly similar conditions.

Tirzepatide: SURMOUNT-1 and the SURMOUNT programme

SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022; NCT04184622) randomised 2,539 adults with obesity (or overweight with comorbidities) without type 2 diabetes to tirzepatide 5mg, 10mg, or 15mg weekly, or placebo, for 72 weeks. Mean body weight change at week 72 was -15.0% at 5mg, -19.5% at 10mg, and -20.9% at 15mg, versus -3.1% with placebo. Mean values were subsequently reported as up to 22.5% in responder analyses, which is the figure most commonly quoted. At 15mg, 56.7% of participants achieved at least 20% body weight loss, a threshold previously associated with bariatric surgery.

SURMOUNT-2 extended the programme to adults with obesity and type 2 diabetes. SURMOUNT-3 tested tirzepatide after a 12-week intensive lifestyle lead-in. SURMOUNT-4 assessed weight maintenance after open-label induction. SURMOUNT-5 (Aronne et al., NEJM, 2025; NCT05822830) was the first head-to-head weight loss trial in the class: 751 adults with obesity and at least one comorbidity (hypertension, dyslipidemia, OSA, or cardiovascular disease) randomised 1:1 to the maximum tolerated dose of tirzepatide (10mg or 15mg) or semaglutide (1.7mg or 2.4mg) over 72 weeks. Mean weight loss was 20.2% with tirzepatide versus 13.7% with semaglutide, a 47% relative improvement. Tirzepatide participants were more than twice as likely to achieve 25% body weight loss (31.6% vs 16.1%). Gastrointestinal discontinuation was higher on semaglutide (5.6%) than tirzepatide (2.7%). Tirzepatide is currently the only compound in the class with a published head-to-head weight loss win over semaglutide.

Retatrutide: TRIUMPH-4 and Phase II

The Phase II obesity trial (Jastreboff et al., NEJM, 2023) tested retatrutide across multiple doses in 338 adults over 48 weeks. The 12mg arm produced a mean body weight reduction of -24.2%, with no plateau visible at trial end. The Phase II programme also reported reductions in intrahepatic fat of up to 86% at the highest dose as measured by MRI-PDFF, an effect size larger than anything previously published in the class.

TRIUMPH-4 (NCT05931367) reported topline results on December 11, 2025. The trial enrolled 1,632 adults with obesity and knee osteoarthritis. At 68 weeks, the 12mg dose produced -28.7% body weight reduction, the 9mg dose produced -26.4%, and placebo produced -2.1%. Systolic blood pressure fell by 14.0 mmHg at 12mg. WOMAC pain scores improved by -4.4 points at 12mg versus -2.4 on placebo. Seven additional Phase III readouts from the TRIUMPH programme (including TRIUMPH-1 for general obesity and TRIUMPH-3 for cardiovascular outcomes) are expected through 2026.

The diabetes picture

Tirzepatide's SURPASS programme (SURPASS-1 through SURPASS-5) established its diabetes profile. In SURPASS trials, tirzepatide at 15mg produced A1C reductions of 1.7% to 2.4% and weight loss of 7% to 9% in diabetes populations. Retatrutide's first diabetes Phase III readout, TRANSCEND-T2D-1 (March 19, 2026), produced a 2.0% A1C reduction and 16.8% body weight loss at 12mg over 40 weeks. Weight loss had not plateaued at week 40, which is unusual for the class. In diabetes populations, retatrutide's weight loss advantage over tirzepatide appears even larger than in non-diabetic populations.

Practical breakdown: dosing, administration, tolerability

Both compounds are once-weekly subcutaneous injections. Both require titration to manage gastrointestinal side effects. The schedules and dose options differ meaningfully.

Tirzepatide titration (Zepbound)

• Weeks 1 to 4: 2.5mg weekly (initiation dose, not therapeutic)
• Weeks 5 to 8: 5mg weekly
• Weeks 9 to 12: 7.5mg weekly
• Weeks 13 to 16: 10mg weekly
• Weeks 17 to 20: 12.5mg weekly
• Week 21 onward: 15mg weekly (full maintenance)

Tirzepatide's labelled maintenance options include 5mg, 10mg, and 15mg. Clinicians often stop titration earlier if the patient is losing weight well at a lower dose or if tolerability drives the decision. 5mg alone produces 15% weight loss in trials, which is comparable to semaglutide 2.4mg at its maximum.

Retatrutide titration (as used in TRIUMPH-4)

• Weeks 1 to 4: 2mg weekly
• Weeks 5 to 8: 4mg weekly
• Weeks 9 to 12: 6mg weekly
• Weeks 13+: 8mg, 9mg, or 12mg maintenance depending on arm

Retatrutide's titration is faster per step (4-week intervals) than tirzepatide's (4-week intervals starting at lower absolute doses, but with more steps). The real-world approved schedule will likely be determined by TRIUMPH-1 and label negotiations, and may include slower options given the Phase III discontinuation rates.

Gastrointestinal events in TRIUMPH-4 at 12mg retatrutide: nausea 43%, vomiting 21%, diarrhea 33%. In SURMOUNT-1 at 15mg tirzepatide: nausea 31% to 36%, vomiting 12% to 16%, diarrhea roughly 20%. Tirzepatide is broadly the better-tolerated compound on GI endpoints. The more important divergence is dysesthesia, reported in 8.8% of retatrutide patients at 9mg and 20.9% at 12mg, against 0.7% on placebo. Dysesthesia (an abnormal skin sensation including tingling, burning, or numbness) was not reported in Phase II. Lilly stated the events did not generally lead to discontinuation, but analysts flagged the signal as something to track across remaining TRIUMPH readouts.

Discontinuation rates are the other meaningful difference. In TRIUMPH-4, discontinuation was 12.2% at 9mg and 18.2% at 12mg, versus 4% on placebo. In SURMOUNT-1, discontinuation for tirzepatide 15mg was approximately 7%. Some TRIUMPH-4 discontinuations were attributed to "perceived excessive weight loss" in participants with lower baseline BMI. That is a novel finding in the class and suggests the 12mg dose may be too aggressive for many real-world patients.

Direct comparison table

How to think about the gap

Cross-trial comparisons always carry caveats. SURMOUNT-1 enrolled adults with obesity (or overweight plus comorbidities) without diabetes, over 72 weeks. TRIUMPH-4 enrolled adults with obesity and knee osteoarthritis over 68 weeks. The populations, trial durations, and primary endpoints differ enough that the 6.2 percentage point gap between 28.7% and 22.5% should be treated as a reasonable estimate, not a precise measurement. A direct head-to-head trial would settle the question. None has been announced, which is telling. Lilly owns both compounds and has limited commercial incentive to run a trial that could cannibalise tirzepatide sales before retatrutide is launch-ready.

The more interesting comparison is the shape of the efficacy curve. Tirzepatide's weight loss in SURMOUNT-1 had largely plateaued by week 72. Retatrutide's weight loss in the 48-week Phase II trial had not plateaued, and the 68-week TRIUMPH-4 readout suggests the trajectory continued to decline throughout the trial. If retatrutide produces continued weight loss beyond 68 weeks (a pattern TRANSCEND-T2D-1 also showed), the real efficacy gap over longer durations could widen. Alternatively, if the discontinuation rate increases at higher baseline BMI thresholds or longer durations, the real-world gap could narrow.

Real-world performance is the other variable worth flagging. Published real-world evidence for tirzepatide through 2025 has consistently shown weight loss running a few percentage points below trial benchmarks: roughly 15% to 18% average at 12 months on 15mg, compared with the 20% to 22% seen in SURMOUNT-1. The gap is driven by incomplete dose escalation (many patients never reach 15mg), lower adherence than in monitored trials, and insurance-driven interruptions. Retatrutide will face the same real-world drag once approved. The 28.7% trial headline will translate to something lower in routine practice, and the 28.7% versus 22.5% comparison may compress in the real world to something closer to 22% versus 17%.

On access and cost, tirzepatide is available now. Zepbound's US list price is approximately $1,060 to $1,350 per month with significant variation by payer and manufacturer copay programmes. Retatrutide pricing will be set by Lilly after approval; analyst estimates cluster around $1,200 to $1,500 per month, broadly comparable. For a patient starting treatment today, tirzepatide is the available option and is likely to remain so until at least 2027. Waiting two or three years for retatrutide carries an opportunity cost: the metabolic benefits of 22.5% weight loss on tirzepatide today are real and compound over time.

For clinicians and patients thinking about sequencing: tirzepatide first is the default. If weight loss plateaus below goal or tolerability becomes limiting, retatrutide would be the second-line option once available. The reverse (starting retatrutide and de-escalating to tirzepatide) is mechanistically possible but would not be a standard pathway. Our Retatrutide File covers the compound in depth, our Tirzepatide File covers the approved dual agonist, and the three-way comparison adds semaglutide to the picture. For the two-way semaglutide comparison, see Retatrutide vs Semaglutide.

Frequently asked questions